These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 12056923)

  • 21. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
    Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
    J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nicotinic Cholinergic Mechanisms in Alzheimer's Disease.
    Shen J; Wu J
    Int Rev Neurobiol; 2015; 124():275-92. PubMed ID: 26472533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.
    Lawrence AD; Sahakian BJ
    Neurochem Res; 1998 May; 23(5):787-94. PubMed ID: 9566619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholinergic and glutamatergic drugs in Alzheimer's disease therapy.
    Clarke NA; Francis PT
    Expert Rev Neurother; 2005 Sep; 5(5):671-82. PubMed ID: 16162091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease?
    Martorana A; Esposito Z; Koch G
    CNS Neurosci Ther; 2010 Aug; 16(4):235-45. PubMed ID: 20560995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A role of alpha-7 nicotinic acetylcholine receptors in pharmacotherapy of neurodegenerative diseases].
    Makotrova TA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(10 Pt 2):57-9. PubMed ID: 23250612
    [No Abstract]   [Full Text] [Related]  

  • 27. 5-Desmethylnobiletin augments synaptic ACh levels and nicotinic ACh receptor activity: A potential candidate for alleviation of cholinergic dysfunction.
    Trivedi S; Maurya P; Sammi SR; Gupta MM; Pandey R
    Neurosci Lett; 2017 Sep; 657():84-90. PubMed ID: 28780166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-7 Nicotinic Receptors in Nervous System Disorders: From Function to Therapeutic Perspectives.
    De Jaco A; Bernardini L; Rosati J; Tata AM
    Cent Nerv Syst Agents Med Chem; 2017; 17(2):100-108. PubMed ID: 27488345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl).
    Maelicke A
    Int J Clin Pract Suppl; 2001 May; (120):24-8. PubMed ID: 11406923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease.
    Levy ML; Cummings JL; Kahn-Rose R
    Gerontology; 1999; 45 Suppl 1():15-22. PubMed ID: 9876214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic treatment of cognition in Alzheimer's dementia.
    Farlow MR; Evans RM
    Neurology; 1998 Jul; 51(1 Suppl 1):S36-44; discussion S65-7. PubMed ID: 9674761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Acetylcholinesterase inhibitors in Alzheimer's disease: further comments on their mechanisms of action and therapeutic consequences].
    Nieoullon A
    Psychol Neuropsychiatr Vieil; 2010 Jun; 8(2):123-31. PubMed ID: 20525543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization.
    Levin ED; McClernon FJ; Rezvani AH
    Psychopharmacology (Berl); 2006 Mar; 184(3-4):523-39. PubMed ID: 16220335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
    Geerts H; Grossberg GT
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PET studies and cholinergic therapy in Alzheimer's disease.
    Nordberg A
    Rev Neurol (Paris); 1999; 155 Suppl 4():S53-63. PubMed ID: 10637939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholinergic agonists and the treatment of Alzheimer's disease.
    Messer WS
    Curr Top Med Chem; 2002 Apr; 2(4):353-8. PubMed ID: 11966459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuronal histamine and cognitive symptoms in Alzheimer's disease.
    Zlomuzica A; Dere D; Binder S; De Souza Silva MA; Huston JP; Dere E
    Neuropharmacology; 2016 Jul; 106():135-45. PubMed ID: 26025658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement.
    Stanciu GD; Luca A; Rusu RN; Bild V; Beschea Chiriac SI; Solcan C; Bild W; Ababei DC
    Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31888102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive enhancement therapy for Alzheimer's disease. The way forward.
    Parnetti L; Senin U; Mecocci P
    Drugs; 1997 May; 53(5):752-68. PubMed ID: 9129864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release.
    Zhang L; Zhou FM; Dani JA
    Mol Pharmacol; 2004 Sep; 66(3):538-44. PubMed ID: 15322245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.